BioCina Acquires the Exclusive CDMO Rights for Leading-Edge Minicircle DNA Technology Platform from CelluTx

CelluTx's Chief Executive Officer, Maurits Geerlings said, "We are very pleased to engage with BioCina for the worldwide deployment of the RBPS minicircle DNA technology. BioCina has proven capabilities and the highest commitment to its customers, which has been fundamental to our partnering with BioCina." CelluTx's Chief Executive Officer,Maurits Geerlingssaid, "We are very pleased to engage with BioCina for the worldwide deployment of the RBPS minicircle DNA technology. BioCina has proven...

CelluTx's Chief Executive Officer, Maurits Geerlings said, "We are very pleased to engage with BioCina for the worldwide deployment of the RBPS minicircle DNA technology. BioCina has proven capabilities and the highest commitment to its customers, which has been fundamental to our partnering with BioCina."

Womack added, "Additionally, Australia offers one of the most attractive Tax Incentives available globally (up to 48.5% cash refund), making it an ideal destination for biologics companies looking to invest in scaling-up and manufacturing their products."

About BioCina
BioCina is a global end-to-end biologics Contract Development and Manufacturing Organisation (CDMO), offering highest-quality, cost-effective cell line, process, analytical and formulation development, and cGMP clinical & commercial manufacturing of the microbial, pDNA and mRNA modalities. BioCina's first facility in Adelaide, South Australia is a testament to the quality of its work. It has a rich history of developing and manufacturing both clinical and commercial drug substance, backed by most critical SME's with an average tenure of 15+ years at the site. BioCina boasts an elite quality record having successfully passed regulatory inspections by the US FDA, Health Canada, and EMA. It is licensed by the Australian TGA for cGMP manufacturing of bulk drug substance or active intermediates. Through a partnership with NovaCina, BioCina offers clients a highest-quality fill-and-finish solution. BioCina is proud to have clients globally, including U.S., Europe, and the Asia Pacific. Because BioCina is not a drug developer, it only serves clients' products. BioCina is establishing a second large-scale, high-capacity end-to-end mammalian and microbial facility in Australia, to be ready for client service in 2026.

Australia offers one of the most attractive tax incentives available globally (up to 48.5% cash refund), making it an ideal destination for biologics companies looking to invest in scaling-up and manufacturing products. Learn more at https://biocina.com.

About CelluTx
CelluTx, LLC is a Wayne, PA-based biotech company supporting the cell & gene therapy community through the deployment of the RBPS minicircle DNA Technology invented by Dr. Peter Mayrhofer. The RBPS Technology is designed to provide manufacturing scalability and optimal purity for clinical-grade minicircle DNA. Being devoid of bacterial backbone components, the RBPS Technology provides for safer and more transfection-efficient DNA product, particularly important for CAR-TCR therapies. The RBPS Technology helps optimize various therapeutic application areas where DNA is a critical component, whether it is used as a direct therapeutic, therapeutic intermediate or source for other manufacturing processes. CelluTx has a strategic collaboration with Austria-based Supercoiled Genetics GmbH to support customers at preclinical stage research and development level using the RBPS Technology.

Media Contact
[email protected]

Logo - https://mma.prnewswire.com/media/2346937/BioCina_New_Logo.jpg

Logo - https://mma.prnewswire.com/media/2427713/CelluTlogo_3_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/biocina-acquires-the-exclusive-cdmo-rights-for-leading-edge-minicircle-dna-technology-platform-from-cellutx-302161306.html